Novo Nordisk Balances Medicare Windfall with Supply Chain Squeeze

Medicare's Wegovy coverage opens vast US market for Novo Nordisk, but supplier price cuts aim to protect margins; stock rallies 45% but technical indicators show overbought.

Novo Nordisk is pulling two levers at once. The Danish pharma giant has unlocked a vast new US market through Medicare’s decision to cover its weight-loss drug Wegovy, while simultaneously pressing its own suppliers for price cuts to preserve margins. The twin moves reflect a company trying to ride a demand wave without letting costs erode its profitability.

Shares in Novo Nordisk have recovered sharply from a March low of €30.25, climbing 45% to €43.92 by Thursday. The stock’s 30-day gain now stands at 19.22%, and it sits 14.05% above its 50-day moving average. Yet the initial Medicare announcement left the stock largely flat, closing at €42.88. The muted reaction suggests investors are weighing the promise of higher volumes against the discounts Novo had to grant.

Medicare’s $50 Door Opens

Since the start of July, the US government’s Medicare program has begun covering Wegovy under a temporary initiative called “Medicare GLP-1 Bridge”. Previously, federal law barred the state from paying for standalone obesity treatments. The new scheme targets overweight seniors with co-morbidities such as hypertension. Eligible patients now pay just $50 a month for Wegovy, a steep cut from the list price of nearly $300. The program runs until the end of 2027.

Medicare covers more than 69 million people, and officials expect several million new users to emerge. In exchange for this broad access, Novo Nordisk agreed to a net price of $245 per monthly supply. Rival Eli Lilly accepted similar terms for its own GLP-1 drug. Novo’s US commercial chief Jamey Millar pointed to the drug’s proven ability to reduce heart attack and stroke risk in patients with pre-existing conditions – a strong argument for an older population.

Squeezing Suppliers to Protect Margins

At the same time, Novo Nordisk has sent written requests to its suppliers demanding price reductions. The company says it wants partnerships to remain “commercially viable”, but some suppliers view the move as a clear pressure tactic tied to future contracts. The cost-cutting campaign can be read two ways: either as a sign of strength, with Novo pre-emptively locking in margin protection, or as a defensive response to intensifying competition from Eli Lilly’s tirzepatide franchise.

The supply-chain discipline could help sustain margins even if pricing power in the GLP-1 market continues to erode. But the rally has technical warning flags. The 14-day relative strength index stands at 75.5, deep in overbought territory, while the 30-day annualised volatility of 31.17% underscores how fragile sentiment remains. Over 12 months the stock is still down 25.86%, and it trades 28.24% below its 52-week high of €61.20, set in July 2025.

CagriSema: The Next Catalyst

The most significant upcoming event for the stock is the regulatory review of CagriSema, Novo’s next-generation obesity combination. The company expects the FDA to examine its approval application sometime in 2026. Phase 3 studies, branded REIMAGINE 1 through 3, are testing CagriSema across different diabetes baseline therapies, with results due at a medical symposium. Additional data on Ozempic, Wegovy, and the early-stage candidate Zenagamtide are also in the pipeline.

But the CagriSema story has already suffered a setback. The open-label Phase 3 trial REDEFINE 4 compared a 15-mg weekly dose of CagriSema directly against tirzepatide. After 84 weeks, it failed to prove non-inferiority in weight loss. Full data from REDEFINE 11, which will examine the drug’s maximum obesity-reduction potential, are not expected until the first half of 2027. A Phase 3 study for a higher dose of CagriSema will not start before the second half of 2026.

That leaves a long stretch where supplier pressure and the competitive dynamic with Eli Lilly could continue to weigh on sentiment, regardless of short-term price swings. Two concrete milestones deserve attention: progress on the FDA review in 2026 and the launch of the higher-dose study later that year. Both could reshape the narrative around the stock well before the REDEFINE 11 readout. For now, the rally holds above key moving averages, suggesting a potential bottoming process – even if an overbought RSI warns of a possible pullback.